Cutera (NASDAQ:CUTR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.

According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “

A number of other analysts have also recently commented on CUTR. Roth Capital upped their price objective on Cutera from $41.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday, September 12th. Maxim Group cut Cutera from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. Finally, BidaskClub upgraded Cutera from a “hold” rating to a “buy” rating in a research report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $37.33.

Shares of Cutera (CUTR) opened at $46.95 on Tuesday. The company has a market capitalization of $642.13, a price-to-earnings ratio of 62.60, a P/E/G ratio of 2.00 and a beta of 0.53. Cutera has a 1 year low of $16.75 and a 1 year high of $48.95.

Cutera (NASDAQ:CUTR) last posted its quarterly earnings data on Tuesday, November 7th. The medical device company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.34. The company had revenue of $38.17 million during the quarter, compared to analysts’ expectations of $34.82 million. Cutera had a return on equity of 18.73% and a net margin of 7.99%. Cutera’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.12 earnings per share. analysts expect that Cutera will post 0.55 earnings per share for the current fiscal year.

In other Cutera news, EVP Miguel Pardos sold 10,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $46.70, for a total value of $467,000.00. Following the completion of the sale, the executive vice president now owns 39,698 shares in the company, valued at $1,853,896.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David B. Apfelberg sold 1,000 shares of the company’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $39.90, for a total value of $39,900.00. Following the completion of the sale, the director now owns 10,259 shares of the company’s stock, valued at approximately $409,334.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,950 shares of company stock valued at $1,085,720. Company insiders own 3.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC bought a new position in shares of Cutera in the third quarter worth about $117,000. Legal & General Group Plc boosted its stake in shares of Cutera by 69.6% in the third quarter. Legal & General Group Plc now owns 3,600 shares of the medical device company’s stock worth $149,000 after acquiring an additional 1,477 shares during the period. Nationwide Fund Advisors boosted its stake in shares of Cutera by 8.4% in the second quarter. Nationwide Fund Advisors now owns 7,216 shares of the medical device company’s stock worth $187,000 after acquiring an additional 561 shares during the period. Metropolitan Life Insurance Co. NY bought a new position in shares of Cutera in the first quarter worth about $202,000. Finally, Greenwood Capital Associates LLC bought a new position in shares of Cutera in the third quarter worth about $210,000. 87.64% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Downgrades Cutera (CUTR) to Sell” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2017/12/28/zacks-investment-research-downgrades-cutera-cutr-to-sell.html.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.